Home›Advanced prostate cancer
Advanced prostate cancer: what it means and what can be done
It is worth being clear from the outset: once the disease has spread beyond the prostate, in most cases the goal of treatment is no longer cure. But not curable does not mean not treatable. With proper management, the disease is controlled, progression is delayed and life is extended — today, often for years, and with good quality.
"Advanced" is not one single thing
It is a word that covers very different situations, and confusing them causes unnecessary distress. It is worth knowing which one applies to you:
- Locally advanced. The tumour has gone beyond the limits of the prostate but has not spread to distant sites. Here treatment with curative intent can be considered, generally combining several modalities.
- With affected lymph nodes. An intermediate situation; treatment is more intensive and combined, and the outlook varies with the extent of involvement.
- Metastatic. There are distant lesions, most often in bone. This is the setting in which the goal becomes long-term control of the disease.
That is why the most useful first question is not "how long do I have?" but "which of these situations am I in, exactly?". The answer changes the plan completely.
The essential point
A disease that cannot be cured can still be controlled for a long time. In advanced prostate cancer that difference is enormous: it is now managed as a chronic condition requiring follow-up and adjustment, not as an inevitable short-term outcome.
| Scenario | What it means | Where treatment is heading |
|---|---|---|
| Locally advanced | The tumour has grown beyond the prostate or reached the seminal vesicles, but there are no metastases | Still with curative intent: surgery or radiotherapy, almost always with hormone therapy |
| Biochemical recurrence | The PSA rises again after treatment, with no visible lesion | Locate it with PSMA PET and treat the site of relapse in a targeted way |
| Metastatic hormone-sensitive | There are metastases and they still respond to hormone therapy | Hormone therapy plus a second agent from the outset; radiotherapy to the prostate if the burden is low |
| Castration-resistant | The disease progresses despite testosterone being at minimal levels | Further lines: chemotherapy, radioligands and targeted treatments guided by tumour genetics |
Why this table matters more than it seems
When a patient is told his cancer is "advanced", it is natural to hear a single thing. But between the first row and the last there are years of difference and prognoses that bear no resemblance to one another: locally advanced disease is still treated to cure; castration-resistant disease is treated to prolong life with quality.
Knowing which one you are in is not a technical detail. It is what determines whether the right conversation is about cure, about prolonged control, or about both at once.
What has changed in recent years
If someone in your family went through this one or two decades ago, the picture you remember is no longer the current one. Three changes altered it fundamentally:
- Treating with combinations from the start, rather than holding medications back until the first one stops working.
- Better imaging, which detects the true extent far more accurately and allows treatment to be targeted.
- Genetic testing that in some patients opens up specific treatment alternatives.
The result is not a promise of cure, but it is a real change in how long the disease stays under control and in how that time is lived.
Hormone therapy is the backbone
Prostate cancer depends on testosterone to grow. The fundamental treatment is to suppress that signal, which usually produces a rapid and clear response: a fall in PSA, relief of pain where present, and control of the lesions.
It is an effective treatment, but not a harmless one: it causes hot flushes, fatigue, loss of muscle and bone mass, and changes in sexual desire and mood. All of these effects can be anticipated and managed, and they form part of what should be reviewed at every appointment. They are not a price to be paid in silence.
Combine from the start, do not wait
This is the most important change of recent years. Treatment used to begin with hormone therapy alone, adding others once it stopped working. The evidence now supports combining from the outset: hormone therapy plus an additional targeted medication, and in selected cases chemotherapy.
Which combination applies depends on the extent of the disease, your general condition and any conditions you already have. There is no single regimen, and choosing well at the start matters more than any later adjustment.
The role of surgery and radiotherapy
Advanced disease does not rule out treatment directed at the prostate itself. In patients with low-volume metastatic disease, radiotherapy to the prostate added to systemic treatment has shown benefit. Radiotherapy is also used on specific lesions to control pain.
Surgery has a narrower but relevant role: relieving urinary obstruction, controlling bleeding or, in selected cases of locally advanced disease, forming part of treatment with curative intent.
Protecting the bones
Bone is the most frequent site of spread, and hormone therapy also weakens bone mass. These are two separate fronts addressed at the same time.
The plan therefore includes monitoring bone health, ensuring adequate calcium and vitamin D, maintaining physical activity and, when indicated, using specific medications that reduce the risk of fractures and complications. It is a part of treatment that is often neglected and that directly affects a patient's independence.
Genetic testing matters
In advanced disease it may be appropriate to test for genetic alterations in the tumour and, in certain cases, inherited ones. This has two practical consequences: some alterations open the door to specific treatments, and when they are inherited they mean your close relatives should be assessed.
Why management must be multidisciplinary
This is the central point of the whole page. Advanced prostate cancer is not solved by a single treatment or a single doctor: it requires a Urologic Oncologist to coordinate the plan and work closely with radiation oncology, medical oncology and the supportive care team.
Coordinating means deciding the order of treatments rather than improvising it; anticipating side effects rather than reacting to them; and adjusting the plan when the studies indicate it, without waiting for symptoms to appear. In practice, that continuity is what separates a controlled disease from one that advances unmonitored.
Put plainly: at this stage, who directs the treatment influences the outcome as much as which treatment is chosen.
How the disease is monitored
Follow-up is what makes it possible to act in time. It rests on three elements:
- PSA and its trend over time, which is more informative than any isolated value.
- The testosterone level, to confirm that hormone suppression is effective.
- Imaging studies, at the intervals appropriate to your situation.
When PSA begins to rise steadily, it does not mean the options have run out: it means the time has come to change strategy. There are several lines of treatment, and the order in which they are used is also a decision.
Quality of life is not a secondary matter
Gaining time is meaningful if that time can be lived. That is why pain control, management of the effects of hormone therapy, adapted physical activity, bone health and emotional support for you and your family are part of the treatment, not the small print.
If something is affecting your daily life, saying so in consultation is not complaining: it is clinical information that changes decisions.
Here the decisions accumulate
Why it matters who looks after you
Advanced prostate cancer has ceased to be one disease with one treatment. It is now a long sequence of decisions, each of which conditions those that follow.
- Establishing which scenario you are inLocally advanced, biochemical recurrence, metastatic hormone-sensitive and castration-resistant are different situations with different treatments. Confusing them is the costliest error, and it happens.
- Combining from the outsetThe evidence of recent years changed the order: adding a second agent from the start, rather than waiting for hormone therapy to fail, prolongs life. There are still patients being treated with the regimen of fifteen years ago.
- Not abandoning local treatmentIn low-volume metastatic disease, treating the prostate with radiotherapy improves survival. It is a decision that gets lost when a case passes wholesale into systemic management without urological input.
- Testing the genetics and coordinating the teamCertain alterations open up targeted treatments and have implications for your family. And management requires medical oncology, radiotherapy and urology talking to one another, not three parallel appointments that never meet.
What I mean is simple: in this disease almost nobody gets an operation wrong; months are lost in the decisions in between. That is where it matters who is coordinating.
A urologic oncologist is a urologist who additionally completed a postgraduate fellowship devoted solely to urological cancer. Mine was at Centro Médico Nacional Siglo XXI, accredited by UNAM. It can be verified. What exactly changes →
What to bring to your appointment
- The full pathology report and, if available, any genetic testing report.
- All imaging studies, on disc or with digital access — including earlier ones, so they can be compared.
- The full sequence of your PSA values with their dates.
- The exact list of treatments you have already received, with start and stop dates, and the reason for any change.
- Your current medications and any conditions you have.
- Written down on paper, the questions that matter to you. And, if you can, bring someone with you.
Related guides
If your disease is confined to the gland, the guide on localized prostate cancer describes the options with curative intent. And if it all began with an abnormal blood test, the guide on elevated PSA may help.
Very professional. He has my complete confidence. I trust in God and in Dr. Eduardo that I will come through this.
Álvaro Verified appointment · Doctoralia · translated from Spanish
Dr. Eduardo Amaya Fragoso
Urologic Oncologist · Robotic Surgeon
Looking for a second opinion on your treatment?
Bring your studies, your PSA history and the treatments you have already received. We will review together where the disease stands, whether the current regimen is the right one and which options remain available. A second opinion neither interrupts your treatment nor commits you to anything.
Available in person and by video consultation
Where I practise
Hospital San José, Hermosillo
Suite 301 · Module H · 3rd floor
Blvd. José María Morelos 340, Col. Bachoco, ZIP 83148
Hermosillo, Sonora
Appointments & info
662 111 0782
Hours
Monday to Friday · 8:00 AM – 8:00 PM
Saturday · 9:00 AM – 2:00 PM
Coming from another city? Travel times, length of stay and remote follow-up
Note
This information is for general guidance and does not replace a medical consultation. Advanced prostate cancer covers very different situations: do not make decisions about tests or treatment based on this text without discussing it with your urologist.